Coste MP, Hernández MV

Language: Spanish
References: 23
Page: 11-18
PDF size: 304.63 Kb.

Text Extraction

No abstract.

REFERENCES

1. Lew E. Peptic Ulcer Disease. Current Diagnosis and Treatment 3rd Edition. 2016; III: 197-208.

2. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 1500- 1511.

3. Sung JJ, Kuipers EJ, El- Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009; 29: 938- 946.

4. Feinstein LB, Holman RC, Yorita KL, et al. Trends in hospitalizations for peptic ulcer disease, United States, 1998- 2005. Emerg Infect Dis. 2010; 16: 1410- 1418.

5. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2:3.

6. Lin KJ, García LA, Hernández S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Pharmacoepidemiol Drug Saf 2011; 20:718.

7. Tytgat G. Etiopathogenetic Principles and Peptic Ulcer Disease Classification. Dig Dis 2011;29:454–458.

8. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2:59.

9. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 9 Suppl 2:33.

10. Sigarán M, Hernández F, Rivera P, et al. Incidencia del Helicobacter pylori en la consulta endoscópica de un hospital costarricense. Patología 1992; 30:15-9.

11. Hernández F, Rivera P, Sigarán M, et al. The first cases of Campylobacter (Helicobacter) pylori reported from Costa Rica. Rev Biol Trop 1990; 38: 481-2.

12. Blanco C, Rivera P, Hernández F, et al. Prevalencia de Helicobacter pylori en pacientes atendidos en el Hospital San Juan de Dios, San José, Costa Rica. Rev Biomed 2001; 12:1-4.

13. Melcarne L., Garcia P, Calvet X. Management of NSAID-associated peptic ulcer disease. Expert Review of Gastroenterology & Hepatology. 2016.

14. Charpignon C, Lesgourges B, Pariente A, te al. Peptic ulcer disease: one in five is related to neither Helicobacter pylori nor aspirin/NSAID intake. Aliment Pharmacol Ther. 2013; 38: 946-954.

15. Chen C, Tsung C, Yi L. A systematic approach for the diagnosis and treatment of idiopathic peptic ulcers. Korean J Intern Med 2015;30:559-570.

16. Lu CL, Chang SS, Wang SS, et al. Silent peptic ulcer disease: frequency, factors leading to "silence," and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc 2004; 60:34.

17. Vakil N, Feldman M, Grover S. Peptic ulcer disease: Clinical manifestations and diagnosis. UpToDate 2016.

18. Delaney BC, Qume M, Moayyedi P, et al. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicenter randomized controlled trial. BMJ. 2008; 336: 651- 654.

19. Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg 2010; 251:51.

20. Vakil N. Overview of the complications of peptic ulcer disease. UpToDate 2016.

21. Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010; 152: 101- 113.

22. Vakil N. Peptic ulcer disease: Management. UpToDate 2016.

23. Kiichi S, Junji Y., Taiji A., et al. Evidencebased clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol (2016) 51:177–194.